A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.

Fyfe, D

A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. [electronic resource] - Cancer chemotherapy and pharmacology Jan 2002 - 1-6 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article

0344-5704

10.1007/s00280-001-0389-z doi


Administration, Oral
Adult
Aged
Aged, 80 and over
Amsacrine--administration & dosage
Antineoplastic Agents--administration & dosage
Area Under Curve
Biological Availability
Dose-Response Relationship, Drug
Female
Humans
Injections, Intravenous
Male
Middle Aged
Treatment Outcome